Patents by Inventor Soren Brunak

Soren Brunak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9845344
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: December 19, 2017
    Assignee: HOBA THERAPEUTICS APS
    Inventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Søren Brunak, Lars U. Wahlberg
  • Publication number: 20120184492
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.
    Type: Application
    Filed: December 15, 2011
    Publication date: July 19, 2012
    Applicant: NsGene A/S
    Inventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg
  • Publication number: 20090136552
    Abstract: Disclosed are NsG28, NsG30, NsG32 polypeptides, nucleic acids encoding NsG28, NsG30, NsG32 polypeptides, and antibodies that bind to NsG28, NsG30, NsG32 polypeptides as well as methods of making and using the same.
    Type: Application
    Filed: August 1, 2005
    Publication date: May 28, 2009
    Inventors: Mette Gronborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg
  • Publication number: 20090087474
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on secreted therapeutic proteins, NsG29 and NsG31. NsG29 and Ns31 are members of a newly identified family of growth factors with a specific cystein pattern and characterised by expression in the nervous system. The secreted growth factors have potential for the treatment of disorders of the nervous system. The invention also relates to bioactive NsG29 and NsG31 polypeptide fragments and the corresponding encoding DNA sequences.
    Type: Application
    Filed: January 9, 2006
    Publication date: April 2, 2009
    Inventors: Thomas N. Petersen, Nikolaj Blom, Mette Gronborg, Philip Kusk, Soren Brunak, Teit E. Johansen, Lars U. Wahlberg
  • Publication number: 20070275026
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein. NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.
    Type: Application
    Filed: March 30, 2005
    Publication date: November 29, 2007
    Applicant: NSGENE A/S
    Inventors: Mette Gronborg, Philip Kusk, Nikolaj Blom, Thomas Petersen, Teit Johansen, Soren Brunak, Lars Wahlberg
  • Publication number: 20040072162
    Abstract: The present invention relates to the identification of CTL epitopes by the combination of biochemical assays, statistical matrix calculations, and artificial neural networks. A set of peptide libraries are used to generate complete unbiased matrices representing peptide-MHC interactions used to generate a primary prediction of MHC binding for all possible non-redundant peptides. The best binders are subject to a quantitative biochemical binding assay and subsequently a computerised artificial neural network prediction program built from these in vitro experimental MHC-I binding data. The method further comprises improving the identified epitope by replacing amino acids, and testing the identified CTL epitopes in in vitro and in vivo models.
    Type: Application
    Filed: April 10, 2003
    Publication date: April 15, 2004
    Inventors: Anders Fomsagaard, Soren Brunak, Soren Buus, Sylvie Corbet, Sanne Lise Lauernoller, Jan Hansen
  • Publication number: 20010049585
    Abstract: A method for predicting a set of chemical, physical or biological features related to chemical substances or related to interactions of chemical substances including using at least 16 different individual prediction means, thereby providing an individual prediction of the set of features for each of the individual prediction means and predicting the set of features on the basis of combining the individual predictions, the combining being performed in such a manner that the combined prediction is more accurate on a test set than substantially any of the predictions of the individual prediction means.
    Type: Application
    Filed: January 4, 2001
    Publication date: December 6, 2001
    Inventors: Garry Paul Gippert, Ole Lund, Thomas Nordahl Petersen, Claus Lundegaard, Morten Nielsen, Soren Brunak, Jakob Bohr, Henrik Bohr